


How Are We Doing? Data & Updates


Shitanshu Uppal, MD



Practices with no eligible cases in the denominator and/or missing data from one of the time periods are not shown



MOQC Gynecologic Oncology Measures



Practices with no eligible cases in the denominator and/or missing data from one of the time periods are not shown



MOQC Gynecologic Oncology Measures


MOQC Pathway

104	Chemotherapy intent (curative vs non-curative) documented before or within 2 weeks after administration)
114	NK1 receptor antagonist for low or moderate emetic risk cycle 1 chemotherapy (lower score – better)
115	NK1 receptor antagonist and olanzapine prescribed or administered with high emetic risk chemotherapy
111	GCSF administered to patients who received chemotherapy for non-curative intent
126a	Hospice enrollment
126b	Enrolled in Hospice for over 7 days
126c	Enrolled in Hospice for over 30 days
127	Chemotherapy administered within the last 2 weeks of life

Targeted Measures


Targeted Measures		Target
101b	Tobacco cessation counseling administered or patient referred in the past year	70%
108a	Complete family history document for patients with invasive cancer	35%
123	Days from Debulking Surgery to Chemotherapy	28 days

Chemotherapy Intent (Curative Vs. Non Curative) Documented Before or Within Two Weeks After Administration




MOQC Measure 104 Spring 2023

NK1 Receptor Antagonist Prescribed or Administered for Low or Moderate Emetic Risk Cycle 1 Chemotherapy (Lower Score Better)




MOQC Measure 114 Spring 2023

NK1 Receptor Antagonist and Olanzapine Prescribed or Administered with High Emetic Risk Chemotherapy




GCSF Administered to Patients who Received Chemotherapy for Non Curative Intent (Lower-Score Better)




MOQC Measure 111 Spring 2023

Hospice Enrollment




MOQC Measure 126a Spring 2023

Enrolled in Hospice Over 7 Days




MOQC Measure 126b Spring 2023

Enrolled in Hospice Over 30 Days




MOQC Measure 126c Spring 2023

Chemotherapy Administered Within the Last 2 Weeks of Life (Lower Score Better)



MOQC Measure 127 Spring 2023

MSQC Gynecologic Oncology Measures



MSQC Gynecologic Oncology Measures


MOQC Pathway
Emergency Room Utilization
Readmission Rates
Reoperation Rates
Serious Complications
Surgical Site Infections
Urinary Tract Infections
Venous Thromboembolism

MOQC Pathway	Target
116 Outpatient prescribing of opioids for patients after laparoscopic or open hysterectomy	9 pills



Emergency Room Utilization


Benign Cancer



MSQC Measure FLG_UTIL_ED Spring 2023

Readmission Rates


Benign Cancer



MSQC Measure FLG_RTIL_READM Spring 2023

Reoperation Rates


Benign Cancer



MSQC Measure FLG_UTIL_REOP Spring 2023

Serious Complications


Benign Cancer



MSQC Measure FLG_DASH_CMP_SERIOUS Spring 2023

Surgical Site Infections


SSI Benign SSI SERIOUS Benign SSI Cancer SSI SERIOUS Cancer



MSQC Measure SSI and SSI SERIOUS Spring 2023

Urinary Tract Infections


Benign Cancer



MSQC Measure FLG_DASH_CMP_UTI Spring 2023

Venous Thromboembolism

Benign Cancer



MSQC Measure FLG_DASH_CMP_VTE Spring 2023

Fee Schedule Increase Opportunities



Participation to Qualify for Fee Schedule Increases

2022 Criteria

Level	Criteria
Practice Level	At least one physician and one practice manager from the practice must attend both MOQC Gynecologic Oncology Biannual Meetings during that year
Physician Level	Provider must be enrolled in PGIP for at least one year



Participation to Qualify for Fee Schedule Increases

2023 Pilot Proposal

Points Needed: 100		
Meeting Participation	Points	Notes
Gynecologic Oncology Spring Biannual Meeting Physician Champion	25	If either of the Biannual Meetings is unattended by a practice manager or physician, in order to qualify for additional participation points , the practice manager or physician must schedule a follow up meeting a MOQC project manager for a Biannual Meeting and practice-level overview. Additional participation points can only be used to complete the eligibility points requirement once every two years .
Gynecologic Oncology Spring Biannual Meeting Practice Manager	25	
Gynecologic Oncology Fall Biannual Meeting Physician Champion	25	
Gynecologic Oncology Fall Biannual Meeting Practice Manager	25	

Participation to Qualify for Fee Schedule Increases

Points Needed: 100		
Additional Participation	Points	Description
MiGHT	40	Participate and actively use family health history tool
POEM	40	Participate with a POEM pharmacist
MOQC Steering Committee	30	Attend and actively participate with at least 50% of the meetings within the eligibility year
MOQC Measures Committee	30	Attend and actively participate with at least 50% of the meetings within the eligibility year
Approved MOQC Task Forces or Workgroups	30	Attend and actively participate with at least 50% of the meetings within the eligibility year
Development of educational resources	20	Examples: checklist creation workgroup, clinical trials navigation tool development, podcast expert participation
Presentation at a MOQC Biannual Meeting	20	Gynecologic oncology or medical oncology biannual meetings
Participation with MOQC newsletter	10	Practice spotlight interview, article about best practices, etc.

2023 Fee Schedule Increase Summary

Tobacco Cessation Opportunity	
Collaborative-Wide (with Med Onc)	
Tobacco cessation counseling administered or patient referred in the past year	70%
2% Opportunity	

VBR Measure Opportunity	
Collaborative-Wide - Meet Both	
Days from debulking surgery to chemotherapy start	28 days
Outpatient prescribing of opioids for patients after laparoscopic or open hysterectomy	9 pills
3% Opportunity	

Complete Family History Opportunity	
Practice - Meet Both	
Meet VBR measures	2
Complete family history documented for patients with invasive cancer	35%
Additional 2% Opportunity	

Total eligibility: up to 7%

Tobacco Cessation Opportunity



2023 Fee Schedule Increase Summary

Tobacco Cessation Opportunity	
Collaborative-Wide (with Med Onc)	
Tobacco cessation counseling administered or patient referred in the past year	70%
2% Opportunity	


Gynecologic Oncology Target Opportunity	
Collaborative-Wide - Meet 2	
Days from debulking surgery to chemotherapy start	28 days
Outpatient prescribing of opioids for patients after laparoscopic or open hysterectomy	9 pills
3% Opportunity	

Complete Family History Opportunity	
Practice Meet Both	
Meet VBR measures	2
Complete family history documented for patients with invasive cancer	35%
Additional 2% Opportunity	

Total eligibility: up to 7%

Tobacco Cessation Counseling Administered or Patient Referred in Past Year

– VBR Target 70%



MOQC Measure 101b Spring 2023

Gynecologic Oncology Target Opportunity



2023 Fee Schedule Increase Summary


Tobacco Cessation Opportunity	
Collaborative-Wide (with Med Onc)	
Tobacco cessation counseling administered or patient referred in the past year	70%
2% Opportunity	

Gynecologic Oncology Target Opportunity	
Collaborative-Wide - Meet 2	
Days from debulking surgery to chemotherapy start	28 days
Outpatient prescribing of opioids for patients after laparoscopic or open hysterectomy	9 pills
3% Opportunity	


Complete Family History Opportunity	
Practice Meet Both	
Meet VBR measures	2
Complete family history documented for patients with invasive cancer	35%
Additional 2% Opportunity	

Total eligibility: up to 7%

Days From Debulking Surgery to Chemotherapy Start



Total Oxycodone 5mg pills



– VBR Target: 9 pills

R121 + R221


R221 + R122

R222

MSQC Measure Opioids Prescription Comparison

Morphine Equivalents


Prescribed Consumed Excess



MSQC Measure OPIOIDS Prescription Spring 2023

Oxycodone

Prescribed Consumed Excess



MSQC Measure Oxycodone 5 mg Prescription Spring 2023

Complete Family History Opportunity



2023 Fee Schedule Increase Summary


Tobacco Cessation Opportunity	
Collaborative-Wide (with Med Onc)	
Tobacco cessation counseling administered or patient referred in the past year	70%
2% Opportunity	

VBR Measure Opportunity	
Collaborative-Wide - Meet 2	
Days from debulking surgery to chemotherapy start	28 days
Outpatient prescribing of opioids for patients after laparoscopic or open hysterectomy	9 pills
3% Opportunity	

Complete Family History Opportunity	
Practice Meet Both	
Meet VBR measures	2
Complete family history documented for patients with invasive cancer	35%
Additional 2% Opportunity	

Total eligibility: up to 7%

Complete Family History Document for Patients with Invasive Cancer



MOQC Measure 108a Spring 2023

Discussion

